ad SAS 
beyond its value of the capital invested. Normandy Hadrontherapy SAS 
Since June 2019, IBA ownership in Normandy 
Hadrontherapy SAS remained at 39.81 % (no 
change from 2019) of this entity following 
financing by several public and private players. The objective of this project is to launch the 
development of the worlds first cyclotron-based 
carbon therapy system in Caen, France through 
its subsidiary Normandy Hadrontherapy (NHa), in collaboration with the Normandy Region and 
several other private and public players, including 
SAPHYN 
(SAnte 
et 
PHYsique 
Nucleaire).